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Introduction {#acn3568-sec-0001}
============

Human prion diseases are neurodegenerative disorders characterized by tissue accumulation of a misfolded form (PrP^Sc^) of the cellular prion protein (PrP^C^). They comprise three major phenotypes, namely Creutzfeldt‐Jakob disease (CJD), by far the most common, fatal insomnia (FI) and Gerstmann‐Straüssler‐Scheinker syndrome (GSS).[1](#acn3568-bib-0001){ref-type="ref"}, [2](#acn3568-bib-0002){ref-type="ref"} At variance with CJD and FI, GSS manifests a much slower clinical course and is mainly characterized by amyloid deposition rather than spongiform change in the affected brain tissue.[2](#acn3568-bib-0002){ref-type="ref"}, [3](#acn3568-bib-0003){ref-type="ref"} This major phenotypic difference directly reflects the composition and topology of PrP^Sc^ aggregates. While in CJD and FI PrP^Sc^ accumulates as a full‐length or N‐terminally truncated fragments retaining the glycophosphatidylinositol (GPI) membrane anchor attaching the protein to the cell membrane,[4](#acn3568-bib-0004){ref-type="ref"} in GSS PrP^Sc^ mainly deposits in the extracellular space as unglycosylated anchorless fragments.[2](#acn3568-bib-0002){ref-type="ref"}, [3](#acn3568-bib-0003){ref-type="ref"} GSS was originally described as a parenchymal brain amyloidosis linked to missense or insertional mutations in the prion protein gene (*PRNP*).[2](#acn3568-bib-0002){ref-type="ref"} More recently, however, the discovery of premature truncating mutations in *PRNP* has expanded the phenotypic spectrum of anchorless PrP amyloidosis. The description of a *PRNP* stop‐codon mutation (p.Y145X) in a Japanese with dementia and both parenchymal and vascular PrP‐amyloid,[5](#acn3568-bib-0005){ref-type="ref"}, [6](#acn3568-bib-0006){ref-type="ref"} was followed by the findings of similar mutations at codons 160 (p.Q160X),[7](#acn3568-bib-0007){ref-type="ref"}, [8](#acn3568-bib-0008){ref-type="ref"} 226 (p.Y226X),[9](#acn3568-bib-0009){ref-type="ref"} and 227 (p.Y227X)[9](#acn3568-bib-0009){ref-type="ref"} in patients with progressive dementia and pure PrP‐cerebral amyloid angiopathy (PrP‐CAA), GSS or mixed GSS/PrP‐CAA pathology.[7](#acn3568-bib-0007){ref-type="ref"}, [9](#acn3568-bib-0009){ref-type="ref"}, [10](#acn3568-bib-0010){ref-type="ref"} Most significantly, *PRNP* truncating mutations at codons 163 (p.Y163X) and 203 (p.D203X), have been recently found in patients with chronic diarrhea, progressive autonomic failure, and peripheral polyneuropathy in association with widespread abnormal PrP deposition in peripheral organs and the CNS.[11](#acn3568-bib-0011){ref-type="ref"}, [12](#acn3568-bib-0012){ref-type="ref"} Based on the multiple organ system PrP deposition and the amyloid properties of the protein aggregates in the brain, the term PrP systemic amyloidosis was introduced, irrespectively of the demonstration of the classical pathological hallmarks of systemic amyloidosis.[11](#acn3568-bib-0011){ref-type="ref"}, [13](#acn3568-bib-0013){ref-type="ref"}, [14](#acn3568-bib-0014){ref-type="ref"}

Here, we describe two Italian families with several affected members carrying novel truncating mutations in *PRNP* associated with progressive autonomic failure and variable cognitive impairment.

Subjects and Methods {#acn3568-sec-0002}
====================

The study was performed according to the Helsinki Declaration and approved by local ethics committee. Written informed consent was obtained from all subjects.

Genetic Analysis {#acn3568-sec-0003}
----------------

*PRNP* (Ref. Seq. NM_000311) open reading frame was analyzed according to previously described procedures.[9](#acn3568-bib-0009){ref-type="ref"}

Clinical history {#acn3568-sec-0004}
----------------

Subjects IV‐2A (proband 1) and V‐1B in family 1, and subject III‐6 (proband 2) and III‐5 in family 2 underwent a thorough clinical investigation (Fig. [1](#acn3568-fig-0001){ref-type="fig"}A--C). For deceased patients, clinical data were obtained from medical notes or sought from relatives.

![Pedigree of family 1 (A,B) and family 2 (C). Arrows point out the probands, while bullets indicate the subjects who underwent genetic analysis. Although the patient\'s ancestors of family 1 were traced back to 1850, there was no common founder for family branches A and B; however, the two were likely connected because of the restricted geographical residence area (two cities in adjacent provinces with a cumulative population of \~40,000 people) and the identity of the peculiar genetic mutation. (D and E) Sanger sequencing electropherograms showing the nucleotide sequence surrounding the two mutations (c.478_479insAAGTGTACT resulting in the p.Y163X mutation on the left; c.507C\>A determining the p.Y169X mutation on the right). (F) A confocal study (magnification ×400) of autonomic patterns of innervation in the proband 1 (upper boxes) and a control subject. The leg autonomic innervation of sweat gland (left) and arrector pilorum muscle (right) were analyzed. Nerve fibers are marked in red by specific autonomic markers for sweat gland (VIP, vasoactive intestinal peptide) and arrector pilorum muscle (DβH, dopamine‐beta‐hydroxylase), whereas the collagen staining is shown in green. The innervation analysis revealed an almost total loss of cholinergic and noradrenergic fibres in proband 1 compared to the control subject. (G) Immunohistochemical detection of abnormal PrP in proband 1 (upper box) and in a control subject (magnification ×400). PrP staining with primary antibody 3F4 reveals fine, punctate deposits (arrowhead) in the upper dermis at the transition to epidermis only in the patient (the box in the lower‐right corner shows the PrP deposits at a higher magnification).](ACN3-5-777-g001){#acn3568-fig-0001}

Clinical investigations {#acn3568-sec-0005}
-----------------------

Cardiovascular autonomic function was investigated by means of head‐up tilt test (HUTT), Valsalva maneuver, deep breathing and cold face. Nerve conduction studies were carried out in at least one motor and one sensory nerve and the sympathetic skin response (SSR) evaluated from the palm of the hand and the sole of the foot bilaterally.

Cognitive function was explored by the Mini Mental State Examination and specific neuropsychological batteries for memory, visual‐spatial, attention, and executive performances. Conventional brain MRIs, including diffusion imaging, and voxel proton MR spectroscopy were performed according to standard protocols.

Skin studies {#acn3568-sec-0006}
------------

Studies of skin innervation were performed in 3‐mm punch biopsies from thigh and calf, according to previously published procedures.[15](#acn3568-bib-0015){ref-type="ref"} For PrP immunohistochemistry, paraffin sections from formalin‐fixed tissue blocks were processed using the monoclonal antibody 3F4, according to published protocols.[16](#acn3568-bib-0016){ref-type="ref"}

CSF biomarkers {#acn3568-sec-0007}
--------------

The 14‐3‐3 protein was measured semi‐quantitatively by immunoblotting, whereas total‐tau and neurofilament light (Nfl‐L) proteins were quantitatively analyzed using commercially available kits based on a sandwich ELISA method, as described.[17](#acn3568-bib-0017){ref-type="ref"} Prion RT‐QuIC was performed as described.[18](#acn3568-bib-0018){ref-type="ref"}

Results {#acn3568-sec-0008}
=======

*PRNP* analysis showed a 9‐base pair duplicated fragment, c.478_479insAAGTGTACT, resulting in a p.Y163X stop‐codon mutation in family 1 and a c.507C\>A variant determining a p.Y169X stop‐codon mutation associated with the in‐*cis* missense c.508A\>G (p.S170G) in family 2 (Fig. [1](#acn3568-fig-0001){ref-type="fig"}D--E). The mutation was in‐*cis* with the valine allele at codon 129 in family 1 and with the methionine allele in family 2.

Proband 1 (Fig. [1](#acn3568-fig-0001){ref-type="fig"}A) had medical history unremarkable until the age of 45, when he started complaining of abdominal pain, chronic diarrhea and progressive weight loss eventually requiring parenteral nutrition. In the subsequent 10 years, the patient suffered urinary retention and presented syncopal episodes while standing and during urination. Since 63, he also complained of memory difficulties and confusion. At age of 66, neurologic examination disclosed short‐memory lapses, sluggish reacting pupils, diffuse brisk deep tendon reflexes, apallesthesia at the lower limbs, positive Romberg sign, ataxic gait, and segmental or generalized, both spontaneous and evoked, myoclonus.

Proband 2 (Fig. [1](#acn3568-fig-0001){ref-type="fig"}C) started to complain of abdominal pain, chronic diarrhea, hyporexia and early satiety at age of 40. In the next 20 years, she progressively lost about 50 kg and required parenteral nutrition, developed urinary incontinence, bladder and rectal prolapses, and suffered episodes of dizziness and gait unsteadiness, often immediately after standing. At 61, neurological examination revealed claw‐feet, reduced deep tendon reflexes at lower limbs, bilateral ptosis, and a mild strabismus.

Clinical findings in other affected members and the results of instrumental and laboratory investigations of all subjects are summarized in Tables [1](#acn3568-tbl-0001){ref-type="table-wrap"} and [2](#acn3568-tbl-0002){ref-type="table-wrap"}. Autonomic tests revealed the impairment of both sympathetic and parasympathetic autonomic nervous system, fulfilling the diagnostic criteria for orthostatic hypotension at HUTT in all tested patients.

###### 

Main clinical findings in subjects belonging to families 1 and 2

  Case                   Age at onset   Symptom/s at onset                      Clinical phenotype                                     
  ---------------------- -------------- --------------------------------------- -------------------- ----- ----- ---- ---- ----- ----- ----
  *FAMILY 1 (p.Y163X)*                                                                                                                 
  Proband 1              45             diarrhea                                +++                  +++   ++    ++        \+          ++
  IV‐1A                  56             neurogenic bladder                      \+                   +++   ++         ++               
  III‐1A                 n.a.           urinary retention                                                  yes                         
  V‐1B                   33             diarrhea                                +++                  ++    ++    ++   ++   +/−         
  IV‐2B                  35             insomnia                                \+                         \+              +++   +++   
  III‐2B                 30             diarrhea                                +++                                                    
  II‐2B                  n.a.           n.a.                                    yes                                                    
  II‐3B                  n.a.           psychiatric, cognitive                                                             yes   yes   
  *FAMILY 2 (p.Y169X)*                                                                                                                 
  Proband 2              40             diarrhea                                +++                  +++   ++              +/−         
  III‐5                  40             diarrhea, neurogenic bladder, syncope   +++                  +++   +++   ++   ++               ++
  III‐3                  40             diarrhea                                yes                  yes                               
  I‐1                    n.a.           diarrhea                                yes                                                    

\[OH: orthostatic hypotension; source of clinical history: clinical evaluation for proband 1 and 2, V‐1B, III‐5; medical record for IV‐1A, IV‐2B, III‐2B; amnestic for III‐1A, II‐2B, II‐3B, III‐3, I‐1\].

+mild; ++moderate; +++severe; n.a.:not available.
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###### 

Results of laboratory investigations

                                                    Family 1 (p.Y163X)                                                                 Family 2 (p.Y169X)                                                                                                              
  ------------------------------------------------- ---------------------------------------------------------------------------------- ----------------------------------------------------------------- ------------------------------------------------------------- -------------------------
  Cardiovascular reflexes                                                                                                                                                                                                                                              --
  *HUTT* (3^rd^ min):                               pathological                                                                       pathological                                                      pathological                                                  
  ΔSBP, ΔDBP (mmHg); ΔHR (bpm)                      −50, −30; 8                                                                        −3, −17; --                                                       −54, −38; −4                                                  
  Valsalva ratio                                    1.01                                                                               --                                                                1.06                                                          
  Overshoot (mmHg)                                  absent                                                                             1.27                                                              absent                                                        
  Deep breathing:                                   absent arrhythmia                                                                  --                                                                absent arrhythmia                                             
  Cold Face (3^rd^ min):                                                                                                                                                                                                                                               
  ΔSBP, ΔDBP (mmHg); ΔHR (bpm)                      5, −4; −2                                                                          --                                                                23, 15; −2                                                    
  Electromyography                                  sensorimotor axonal PNP                                                            normal                                                            normal                                                        sensorimotor axonal PNP
  Skin sympathetic response                         absent                                                                             absent                                                            absent                                                        absent
  Cognitive dysfunction                             mild global impairment (MMSE 23/30) with memory and visual attention dysfunction   globally normal (MMSE 30/30), but visuo‐spatial task impairment   globally normal (MMSE 26/30), but visual memory dysfunction   --
  Electroencephalography                            mild slowing                                                                       --                                                                normal                                                        --
  Brain MRI[a](#acn3568-note-0005){ref-type="fn"}   nonspecific WM hyperintensities                                                    normal                                                            nonspecific WM hyperintensities                               --
  H^1^‐MRS[a](#acn3568-note-0005){ref-type="fn"}    normal                                                                             --                                                                normal                                                        --
  Skin innervation analysis                         autonomic SFN                                                                      autonomic and somatic SFN                                         autonomic and somatic SFN                                     --
  Skin PrP immunostaining                           positive                                                                           --                                                                negative                                                      --
  Cerebrospinal fluid analysis                                                                                                         --                                                                --                                                            --
  Total proteins (mg/dL)                            215                                                                                                                                                                                                                
  14.3.3 protein assay                              positive                                                                                                                                                                                                           
  Total tau protein (pg/mL)                         17,900                                                                                                                                                                                                             
  Nf‐L (pg/mL)                                      10,200                                                                                                                                                                                                             
  Prion RT‐QuIC                                     negative                                                                                                                                                                                                           

Performed at the age of 66 in proband 1 and at the age of 60 in proband 2. -- , Not done. \[HUTT, head‐up tilt test; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate (bpm, beats per minute); PNP, polyneuropathy; MMSE, Mini Mental State Examinantion (normal value \>24); WM, white matter; SFN, small fiber neuropathy; H^1^‐MRS, brain single voxel proton magnetic resonance spectroscopy (thalamus and cerebellum were analyzed in proband 1, parietal and occipital white matter in proband 2); Nf‐L, neurofilament light chain protein; prion RT‐QuIC, detection of prion seeding activity using real‐time quaking induced conversion assay\].
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Neurophysiologic studies revealed a sensorimotor axonal polyneuropathy in two out of four tested patients and the absence of SSR in all. Neuropsychological tests showed, in proband 1, a selective deficit of visual attention, verbal memory and logical reasoning at age of 65 progressing to a multi‐domain mild cognitive impairment 1 year later. Moreover, they revealed a selective deficit of visual memory or visuo‐spatial performances in other tested patients. Brain MRIs, including proton spectroscopy of the thalamus and cerebellum (proband 1) or the parieto‐occipital white matter (proband 2), were uninformative in all examined patients. Skin innervation analysis revealed a severe small fiber neuropathy with somatic and/or autonomic involvement (Fig. [1](#acn3568-fig-0001){ref-type="fig"}F). PrP immunohistochemistry disclosed a fine punctate PrP staining in the upper dermis next to the transition to epidermis (Fig. [1](#acn3568-fig-0001){ref-type="fig"}G). At variance, skin punch biopsies from two patients with probable sCJD carrying MM and MV at codon 129 showed no abnormal PrP deposits (data not shown).

The CSF obtained from proband 1 was slightly xantochromic, and showed an increase in total proteins. CSF biomarker assays revealed a positive 14‐3‐3 test, markedly elevated total‐tau and Nfl‐L levels, and a negative prion RT‐QuIC (Table [2](#acn3568-tbl-0002){ref-type="table-wrap"}).

Discussion {#acn3568-sec-0009}
==========

We have characterized the phenotypic traits of an inherited prion disease linked to two novel *PRNP* truncating mutations at codons 163 and 169 affecting several members across multiple generations of two Italian families. The disease showed a typical onset in the third or fourth decade and a mean disease duration of 15--20 years. The hallmarks of the clinical phenotype included a generalized autonomic failure with chronic diarrhea, weight loss, and neurogenic OH and neuropathy. Beside this typical presentation, however, cognitive impairment was an early feature in a minority of cases, in one family.

In genetic prion disease linked to stop‐codon *PRNP* mutations, the anchorless prion protein may spread through the interstitial fluids and vascular compartments.[13](#acn3568-bib-0013){ref-type="ref"} This was elegantly shown in experimental studies using transgenic mice expressing a prion protein lacking the GPI anchor (GPI^−/−^), which demonstrated that the anchorless PrP is secreted from the cells and accumulates in both brain and peripheral organs after scrapie infection, assuming the characteristics of a systemic amyloidosis.[19](#acn3568-bib-0019){ref-type="ref"}

The fact that *PRNP* truncations in humans result in heterogeneous phenotypes ranging from dementia to chronic diarrhea and peripheral neuropathy appears to be in line with the above observations in animal models, although the significant phenotypic heterogeneity between patients carrying different *PRNP* truncations remains unexplained.[5](#acn3568-bib-0005){ref-type="ref"}, [6](#acn3568-bib-0006){ref-type="ref"}, [7](#acn3568-bib-0007){ref-type="ref"}, [8](#acn3568-bib-0008){ref-type="ref"}, [9](#acn3568-bib-0009){ref-type="ref"}, [10](#acn3568-bib-0010){ref-type="ref"}, [11](#acn3568-bib-0011){ref-type="ref"}, [12](#acn3568-bib-0012){ref-type="ref"}, [20](#acn3568-bib-0020){ref-type="ref"}

Dementia in patients carrying *PRNP* stop‐codons has been linked to a GSS‐like neuropathologic phenotype with abundant plaques and neurofibrillary tangles (NFT) and/or to PrP‐CAA.[6](#acn3568-bib-0006){ref-type="ref"}, [7](#acn3568-bib-0007){ref-type="ref"}, [9](#acn3568-bib-0009){ref-type="ref"}, [20](#acn3568-bib-0020){ref-type="ref"} Interestingly, widespread PrP plaques and a substantial amount of tau‐related disease in the form of NFT and neuropil threads also characterized the patients with the phenotype of chronic diarrhea with autonomic failure.[11](#acn3568-bib-0011){ref-type="ref"} In this context, our observation of a minority of patients with early cognitive impairment suggests that the timing of CNS involvement may vary even within subjects carrying the same *PRNP* truncating mutation.

The polymorphic codon 129 in the *PRNP* represents the strongest susceptibility locus in sporadic and acquired prion disease and significantly modulates the phenotype of all forms of prion disease. As in other families with *PRNP* stop‐codons,[6](#acn3568-bib-0006){ref-type="ref"}, [7](#acn3568-bib-0007){ref-type="ref"}, [20](#acn3568-bib-0020){ref-type="ref"} both age at onset and clinical phenotype in our patients were not affected by the genotype at codon 129 either in the mutated or wild‐type allele. Moreover, the lack of disease in obligate carriers in family 2 strongly suggests that the penetrance of the truncating *PRNP* mutations may be incomplete, as previously reported in a family carrying the *PRNP* p.Y160X.[20](#acn3568-bib-0020){ref-type="ref"}

The possibility of a prion‐related systemic amyloidosis in patients presenting with slowly progressive symptoms and signs of autonomic and sensory neuropathy is still poorly recognized. Indeed, the diagnostic delay in our patients was remarkable. Most patients are initially referred to a gastroenterologist, and unhelpful tests and misdiagnoses are common, especially in the early clinical stages. Thus, *PRNP* genetic testing should be recommended in all patients presenting with insidious generalized autonomic failure, and a positive family history of autonomic failure and/or cognitive decline. Moreover, the significance and potential diagnostic role of the unexpected increase in CSF neurodegenerative biomarkers we documented in a single patient should be addressed.

In conclusion, based on clinical findings (i.e., peripheral autonomic neuropathy) and the demonstration of PrP deposition in the skin, the present data strengthen the link between *PRNP* truncating mutations and systemic PrP amyloidosis. They also consolidate current knowledge on the clinical expression of these mutations, confirming that dementia and autonomic failure may coexist in the same family and support a wider application of *PRNP* screening to include unsolved cases of familial autonomic polyneuropathy.
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